Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
about
Small molecule compounds that induce cellular senescenceCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.The transcriptome of CDK4/6 inhibitionFbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival.Senescence and tumor suppression.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.Cell-Cycle Therapeutics Come of Age.CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once ThoughtAcquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
P2860
Q28068732-1F865984-7FD4-493C-99DC-1CF1E9AE84D4Q33614544-3716B8D1-E00F-4B5D-B20D-1676ED68AF67Q36224716-7202BE9A-6256-4B64-AD20-1C8E90BE9498Q38644529-56790BD3-9F61-44A6-B0A7-DF71705BE9FDQ39183079-035C33E1-5E3C-4E96-B47A-1A0699DDB31EQ41669833-3D8F2A80-68FC-4C18-BC47-7D070DEFC38DQ46089793-1C4D4352-71E5-491C-B73A-B3BE4DD9E04FQ46132721-06C5FD8E-6BEA-4FF6-895F-36FDE1C84B72Q46244712-F2FD689E-D36E-4B21-8F60-B040D57832DEQ47106101-2E05E760-2917-4051-8978-D174AC4A7F1EQ47316489-B9C6890B-2C9A-4715-8E18-43A304A25F3FQ48113083-218B38D1-7E66-4D90-A133-554428F3E21DQ48169849-145D6086-9DC0-4826-9A27-D06AC7A665FEQ49565626-ACE84A39-DEC9-4F33-9837-A014F36E664CQ49959258-E6F6538C-86A1-490E-9702-84DE17DF988FQ50959563-72275987-A92E-4118-8F06-CB56D07EFB7CQ52592862-A37A09EC-21DE-4536-B768-263B0DDDD523Q52655061-4A6D1277-A32A-48C4-AF3B-AB7BA1DABCEDQ53685801-D486FDAE-7F5C-4EBC-B60E-B993EDE156A1Q55261716-7BBCCC25-6F18-481A-BAFB-59CD9D23887FQ57176702-B51A893C-674A-45A3-B87A-7CF0FF02A758Q58796907-CC071CEB-075E-441B-A6DA-A161722F8E25
P2860
Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@en
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@nl
type
label
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@en
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@nl
prefLabel
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@en
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@nl
P2093
P2860
P1433
P1476
Induction of Therapeutic Senes ...... Extended Inhibition of CDK4/6
@en
P2093
Akihiro Yoshida
Eric K Lee
J Alan Diehl
P2860
P304
P356
10.1158/0008-5472.CAN-15-2931
P407
P577
2016-03-17T00:00:00Z